Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 87Carcinoma, Non-Small-Cell Lung 76Breast Neoplasms 73Recurrence 65Colorectal Neoplasms 63Pancreatic Neoplasms 60Melanoma 58Advanced Solid Tumor 57Multiple Myeloma 56Carcinoma, Hepatocellular 56Lymphoma 53Leukemia, Myeloid, Acute 53Advanced Solid Tumors 53Neoplasm Metastasis 51Stomach Neoplasms 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Lymphoma, B-Cell 40Solid Tumor 39Lymphoma, Non-Hodgkin 39Ovarian Neoplasms 38Lung Neoplasms 36Glioblastoma 35Prostatic Neoplasms 34Leukemia 28Head and Neck Neoplasms 27Leukemia, Lymphocytic, Chronic, B-Cell 26Uterine Cervical Neoplasms 25Burkitt Lymphoma 24Esophageal Neoplasms 23Urinary Bladder Neoplasms 20

Interventions

lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Unknown × First-line Treatment × Clear all
NCT05221775 2022-02-03

Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Tianjin Medical University Cancer Institute and Hospital

Phase 1 Unknown
18 enrolled
Gastrointestinal

First-line Treatment

Data powered by HemOnc (CC BY 4.0) Colophon âš¡